Montelukast%2525252525252525252520levocetrizine

# Montelukast-Levocetirizine (Combination therapy often used for allergic rhinitis and chronic urticaria) ## Overview Montelukast is a selective leukotriene receptor antagonist (LTRA). Levocetirizine is a third-generation, non-sedating H1-receptor antagonist (R-enantiomer of cetirizine). They are often prescribed as a fixed-dose combination or concurrent therapy to provide dual pathways of allergic inflammation control. ## Primary Indications * Allergic Rhinitis (Seasonal and Perennial). * Chronic Urticaria. * Asthma (only for the montelukast component; levocetirizine has no primary role in acute asthma). ## Adult Dosing * **Montelukast:** 10 mg orally once daily in the evening. * **Levocetirizine:** 5 mg orally once daily in the evening. ## Pediatric Dosing * **Ages 6–11 years:** * Montelukast: 5 mg chewable tablet daily. * Levocetirizine: 2.5 mg daily. * **Ages 2–5 years:** * Montelukast: 4 mg chewable tablet or oral granules daily. * Levocetirizine: 1.25 mg (2.5 mL oral solution) daily. * **Ages 6 months – 23 months:** * Montelukast: 4 mg oral granules daily. * Levocetirizine: 1.25 mg daily (safety established per FDA, though use should be confirmed per local clinical protocols). ## Dose Adjustments * **Renal Impairment (Levocetirizine):** Requires dose reduction based on CrCl. If CrCl 30–49 mL/min, 2.5 mg once daily. If CrCl 15–29 mL/min, 2.5 mg every 48 hours. If CrCl <15 mL/min, contraindicated. * **Hepatic Impairment:** No specific adjustment for montelukast; use caution with severe hepatic impairment. ## Contraindications * **Levocetirizine:** End-stage renal disease (CrCl <10 mL/min) and hemodialysis. * **Montelukast:** Known hypersensitivity to the drug. ## Adverse Effects * **Montelukast:** Neuropsychiatric events (aggression, depression, sleep disturbances, suicidal ideation—FDA Boxed Warning recommended), headache, abdominal pain. * **Levocetirizine:** Somnolence (less than cetirizine but significant in sensitive individuals), fatigue, nasopharyngitis, xerostomia. ## Key Drug Interactions * **CYP2C8/3A4 Inhibitors:** May increase montelukast concentrations (e.g., gemfibrozil). * **CNS Depressants:** Alcohol or other sedating agents may potentiate the sedative effects of levocetirizine. * **Ritonavir:** May increase levocetirizine levels. ## Monitoring * **Clinical:** Resolution of allergic symptoms or urticaria. * **Safety:** Monitor for neuropsychiatric changes, particularly in pediatric patients using montelukast. Monitor for excessive somnolence with levocetirizine. ## Clinical Pearls * **Timing:** Administer both medications in the evening to optimize effectiveness for nighttime-to-morning allergic symptoms and to mitigate potential daytime drowsiness from the antihistamine. * **Black Box Warning:** The FDA requires a boxed warning on montelukast regarding serious neuropsychiatric events; clinicians should weigh benefits vs. potential risks, as there are often safer alternatives for allergic rhinitis. * **Granules:** Montelukast oral granules can be placed directly on the tongue or mixed with a spoonful of cold/room-temperature soft food (e.g., applesauce, yogurt). Use within 15 minutes of opening. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice and local protocols may vary significantly. Always verify current prescribing information, package inserts, and hospital guidelines before administering medication. Individual patient factors must be assessed by a licensed practitioner.